We appraised the aberrant expression levels of SNAI2 in pan-cancer compared to human normal tissues, and further examined the upregulated SNAI2 protein and mRNA expression levels in clinical PAAD samples. This evidence concerns the gene SNAI2 and pancreatic adenocarcinoma.